JPWO2019222483A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019222483A5 JPWO2019222483A5 JP2021514939A JP2021514939A JPWO2019222483A5 JP WO2019222483 A5 JPWO2019222483 A5 JP WO2019222483A5 JP 2021514939 A JP2021514939 A JP 2021514939A JP 2021514939 A JP2021514939 A JP 2021514939A JP WO2019222483 A5 JPWO2019222483 A5 JP WO2019222483A5
- Authority
- JP
- Japan
- Prior art keywords
- paragraph
- page
- column
- patent document
- pages
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024021588A JP2024069221A (ja) | 2018-05-17 | 2024-02-16 | グリコーゲンシンターゼキナーゼ３型β阻害剤による特発性肺線維症の治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862672864P | 2018-05-17 | 2018-05-17 | |
| US62/672,864 | 2018-05-17 | ||
| PCT/US2019/032639 WO2019222483A1 (en) | 2018-05-17 | 2019-05-16 | Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024021588A Division JP2024069221A (ja) | 2018-05-17 | 2024-02-16 | グリコーゲンシンターゼキナーゼ３型β阻害剤による特発性肺線維症の治療 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021523951A JP2021523951A (ja) | 2021-09-09 |
| JP2021523951A5 JP2021523951A5 (https=) | 2022-05-24 |
| JPWO2019222483A5 true JPWO2019222483A5 (https=) | 2022-05-24 |
| JP7471660B2 JP7471660B2 (ja) | 2024-04-22 |
Family
ID=68541026
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514939A Active JP7471660B2 (ja) | 2018-05-17 | 2019-05-16 | グリコーゲンシンターゼキナーゼ３型β阻害剤による特発性肺線維症の治療 |
| JP2024021588A Pending JP2024069221A (ja) | 2018-05-17 | 2024-02-16 | グリコーゲンシンターゼキナーゼ３型β阻害剤による特発性肺線維症の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024021588A Pending JP2024069221A (ja) | 2018-05-17 | 2024-02-16 | グリコーゲンシンターゼキナーゼ３型β阻害剤による特発性肺線維症の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12083098B2 (https=) |
| EP (1) | EP3793545A4 (https=) |
| JP (2) | JP7471660B2 (https=) |
| KR (1) | KR20210038429A (https=) |
| CN (1) | CN112437663A (https=) |
| AU (1) | AU2019271285B2 (https=) |
| BR (1) | BR112020023422A2 (https=) |
| CA (1) | CA3100381A1 (https=) |
| IL (1) | IL278761B2 (https=) |
| MX (1) | MX2020012331A (https=) |
| WO (1) | WO2019222483A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020415440A1 (en) * | 2019-12-26 | 2022-08-04 | Actuate Therapeutics, Inc. | Compounds for the treatment of myelofibrosis |
| US20250325517A1 (en) * | 2022-06-27 | 2025-10-23 | Actuate Therapeutics, Inc. | Oral dosage forms of elraglusib |
| CN117981712B (zh) * | 2023-07-24 | 2025-02-28 | 南京鼓楼医院 | 一种腺病毒诱导肺纤维化急性加重动物模型的建立方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2622987C (en) | 2005-09-20 | 2018-02-27 | New York University | Method of treating pulmonary disease with interferons |
| CA2673368C (en) | 2006-12-19 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders |
| JP6021117B2 (ja) | 2011-01-31 | 2016-11-02 | ジェノア ファーマシューティカルズ，インク． | エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用 |
| KR101862291B1 (ko) * | 2011-04-12 | 2018-05-29 | 모레 매트릭스 인코포레이티드 | 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정을 예방하거나 치료하기 위한 조성물 및 방법 |
| US20160375006A1 (en) | 2012-10-12 | 2016-12-29 | The Broad Institute, Inc. | Uses of paralog-selective inhibitors of gsk3 kinases |
| JP2015535233A (ja) | 2012-10-31 | 2015-12-10 | ガレクト・バイオテック・エイビイ | ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用 |
| WO2014165851A1 (en) | 2013-04-05 | 2014-10-09 | The Children's Hospital Of Philadelphia | Transient up-regulation of myc in b-cell lymphomas |
| JP6799201B2 (ja) | 2013-07-31 | 2020-12-16 | アヴァリン ファーマ インク． | エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用 |
| US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| JP6534098B2 (ja) | 2014-09-12 | 2019-06-26 | 国立大学法人 鹿児島大学 | 成人ｔ細胞白血病治療薬 |
| EP3665176B1 (en) * | 2017-08-11 | 2024-01-24 | Actuate Therapeutics Inc. | Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione |
| PL3697794T3 (pl) * | 2017-10-16 | 2026-04-07 | Actuate Therapeutics Inc. | Stałe postacie 3-(5-fluorobenzofuran-3-ylo)-4-(5-metylo-5h-[1,3]dioksolo[4,5-f]indol-7-ilo)pirolo-2,5-dionu |
-
2019
- 2019-05-16 WO PCT/US2019/032639 patent/WO2019222483A1/en not_active Ceased
- 2019-05-16 MX MX2020012331A patent/MX2020012331A/es unknown
- 2019-05-16 IL IL278761A patent/IL278761B2/en unknown
- 2019-05-16 CA CA3100381A patent/CA3100381A1/en active Pending
- 2019-05-16 CN CN201980041162.0A patent/CN112437663A/zh active Pending
- 2019-05-16 EP EP19803888.7A patent/EP3793545A4/en not_active Withdrawn
- 2019-05-16 JP JP2021514939A patent/JP7471660B2/ja active Active
- 2019-05-16 AU AU2019271285A patent/AU2019271285B2/en active Active
- 2019-05-16 KR KR1020207035908A patent/KR20210038429A/ko not_active Ceased
- 2019-05-16 BR BR112020023422-2A patent/BR112020023422A2/pt unknown
- 2019-05-16 US US17/056,238 patent/US12083098B2/en active Active
-
2024
- 2024-02-16 JP JP2024021588A patent/JP2024069221A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Peters et al. | Colchicine in the treatment of pulmonary fibrosis | |
| Hiller et al. | Pulmonary manifestations of the yellow nail syndrome | |
| JP2021523951A5 (https=) | ||
| JP7688910B2 (ja) | 線維化、炎症、及び／又は老化疾患に対する治療薬 | |
| JP2018511327A5 (https=) | ||
| JP2023166406A5 (https=) | ||
| MX2025004532A (es) | Método para tratar el cáncer | |
| JPWO2019222483A5 (https=) | ||
| Zeng et al. | Systematic biological and proteomics strategies to explore the regulation mechanism of Shoutai Wan on recurrent spontaneous Abortion's biological network | |
| JP2020530497A5 (https=) | ||
| Zlateska et al. | Treatment of dyskeratosis congenita‐associated pulmonary fibrosis with danazol | |
| Lim et al. | Clinical features of interstitial lung diseases | |
| WO2022031606A3 (en) | Compositions and methods for treating alzheimer's disease | |
| JPWO2023107938A5 (https=) | ||
| Mosa | Primary Pulmonary Resection in Madagascar: Indication and Results | |
| CN309953039S (zh) | 沙发（单人12） | |
| CN309723706S (zh) | 眼镜（7510） | |
| Chacko et al. | Timing of Renal Replacement Therapy in Critically Ill Patients with Acute Kidney Injury: The AKIKI Trial | |
| CN309932518S (zh) | 沙发（8622） | |
| CN309953064S (zh) | 沙发（单人14） | |
| JPWO2020237172A5 (https=) | ||
| CN309904591S (zh) | 沙发（流年断章） | |
| JPWO2021230993A5 (https=) | ||
| Duitman et al. | Detrimental role for CCAAT/enhancer binding protein δ in blood-borne brain infection | |
| CN309953016S (zh) | 沙发（单人10） |